Globus Medical, Inc. $GMED Shares Acquired by Swedbank AB

Swedbank AB lifted its position in Globus Medical, Inc. (NYSE:GMED) by 6.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 562,403 shares of the medical device company’s stock after acquiring an additional 32,000 shares during the period. Swedbank AB’s holdings in Globus Medical were worth $48,457,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Advisory Services Network LLC acquired a new stake in Globus Medical during the 3rd quarter worth about $26,000. EverSource Wealth Advisors LLC boosted its position in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the period. Parallel Advisors LLC raised its position in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC lifted its stake in Globus Medical by 485.4% during the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after acquiring an additional 631 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GMED has been the topic of a number of research reports. Piper Sandler cut their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday, June 15th. Needham & Company LLC lifted their price objective on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Finally, Wells Fargo & Company dropped their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $105.42.

Insider Buying and Selling at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 18.38% of the stock is currently owned by corporate insiders.

Globus Medical Stock Performance

GMED stock opened at $76.23 on Thursday. The firm has a market cap of $10.35 billion, a PE ratio of 17.73, a P/E/G ratio of 1.63 and a beta of 0.95. The firm’s fifty day moving average is $81.13 and its 200 day moving average is $86.97. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the prior year, the firm posted $0.68 earnings per share. The company’s revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.